Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Defining trajectory in severe asthma: can it be changed?

Inês Farinha, Liam G. Heaney
European Respiratory Journal 2023 62: 2301281; DOI: 10.1183/13993003.01281-2023
Inês Farinha
1Pulmonology Department, Coimbra Hospital and University Centre, Coimbra, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Inês Farinha
  • For correspondence: i.t.farinha@gmail.com
Liam G. Heaney
2Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

The intrinsic variability of asthma across time is a well-known feature of the disease and stratifying disease severity is an integral component of asthma management [1]. Severe asthma is estimated to comprise up to 10% of the asthmatic population and is associated with substantial socioeconomic burden, with more than half of asthma-related healthcare costs being attributed to this level of severity [2–4]. It is associated with recurrent symptoms, increased risk for exacerbations, loss of lung function, fixed airflow obstruction and adverse side-effects of corticosteroids [5–9]. Despite this significant burden, and even though phenotypic changes from childhood to early adulthood have been previously described, little is known about the longitudinal trajectory towards severe asthma in adulthood [10, 11]. Chen et al. [12] performed a retrospective study on 13 467 asthma patients and found that 10 years after new-onset severe asthma, 83% of them had transitioned into a mild-to-moderate level of severity. A prospective cohort study aiming to characterise the long-term trajectory of mild asthma in 125 patients aged >16 years found that 92% of patients remained in the mild state over the following 10 years, and that inappropriate use of rescue therapy, older age and comorbidity were independently associated with an increased risk of progression from mild asthma [1]. However, a different progression trend was described by Haselkorn et al. [13], who found that approximately 50% of patients with severe or difficult-to-treat asthma had very poorly controlled asthma after more than 10 years of follow-up.

Tweetable abstract

Four trajectories towards developing severe asthma have been identified, suggesting different patterns of progression of severity. This may support the need for targeting patients at high risk of progression and to provide early management strategies. https://bit.ly/44alkqL

Footnotes

  • Conflict of interest: I. Farinha has received support for attending meetings from GSK, and has received payment or honoraria from AstraZeneca. L.G. Heaney has had grants or contracts from AstraZeneca, GSK, MedImmune, Novartis, Roche/Genentech, Schering Plough and Synairgen, as monies paid to the institution for the conduct of clinical trials; has received payment or honoraria from AstraZeneca, Chiesi, Circassia, GSK, Novartis, Roche/Genentech, Sanofi and Teva; has received support for attending meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, GSK and Teva; and has participated in data safety monitoring boards or advisory boards for Evelo Biosciences, GSK, Novartis, Roche/Genentech, Teva, Theravance and Vectura.

  • Received August 2, 2023.
  • Accepted August 11, 2023.
  • Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Defining trajectory in severe asthma: can it be changed?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Defining trajectory in severe asthma: can it be changed?
Inês Farinha, Liam G. Heaney
European Respiratory Journal Sep 2023, 62 (3) 2301281; DOI: 10.1183/13993003.01281-2023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Defining trajectory in severe asthma: can it be changed?
Inês Farinha, Liam G. Heaney
European Respiratory Journal Sep 2023, 62 (3) 2301281; DOI: 10.1183/13993003.01281-2023
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Tweetable abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • All roads lead to COPD… or not?
  • Insights in the biology of IL-33 and relevance for COPD
  • Sotatercept, haemodynamics and the right ventricle
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society